FP347
4290MW
Dr.TARNOOM ABDULREHMAN ATHANI
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 4290MW | Dr.TARNOOM ABDULREHMAN ATHANI | tarnoom.athani@gmail.com | 9632661975 |
Orbit & Oculoplasty
Efficacy of IV methylprednisolone and Mycophenolate in active moderate to severe thyroid eye disease
Purpose To evaluate outcomes of IV methylprednisolone pulse therapy with mycophenolate in active, moderate-to-severe thyroid eye disease [TED]. Methods 32 patients [52 eyes] with active TED [CAS ≥3] and moderate-to-severe disease per 2021 EUGOGO criteria received IVMP 4.5g cumulative dose. Mycophenolate 1g/day for 24 weeks was added in 22 patients. Thyroid function tests, CAS, Hertel exophthalmometry, BCVA, color vision, extraocular motility, diplopia assessment, and orbital imaging [CT/MRI]. 6-month outcomes: CAS, proptosis, diplopia, BCVA, and adverse events. Results Mean CAS decreased from 6.9±1.3 to 0.8±0.7. Remission in 28 patients [87.5%]. Proptosis reduced ≥2 mm in 35/52 eyes [67.3%]. Diplopia resolved in 12/24 patients [50%]. Extraocular motility improved in 19/32 patients [59.4%]. No serious adverse events. Conclusion IVMP with mycophenolate is safe and effective for active moderate-to-severe TED, achieving disease remission and significant functional and cosmetic improvement.
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 1679 | Dr.Anand G Gannur | anandggannur@yahoo.com | 9481630838 |
| 1680 | Dr.Madhu | madhu087@gmail.com | 9844860275 |
| 4646 | Dr.Shylaja P Biradar | shylajag8@gmail.com | 9894944021 |